Inotropic therapy for heart failure.

Looking back reveals how the direction of therapy for heart failure has changed since the inception of the first large clinical trial of vesnarinone, an inotropic agent, in April 1990. At that time...

[1]  D. DeMets,et al.  A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart Failure , 1998 .

[2]  B. Massie,et al.  Optimizing therapy for complex or refractory heart failure: a management algorithm. , 1998, American heart journal.

[3]  A. Moskowitz,et al.  Quality of life with an implanted left ventricular assist device. , 1997, The Annals of thoracic surgery.

[4]  W. Abraham,et al.  Specialized centers for heart failure management. , 1997, Circulation.

[5]  T. Rector,et al.  Use of the Living With Heart Failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death. , 1995, Journal of cardiac failure.

[6]  B. Massie,et al.  Can Further Benefit Be Achieved by Adding Flosequinan to Patients With Congestive Heart Failure Who Remain Symptomatic on Diuretic, Digoxin, and an Angiotensin Converting Enzyme Inhibitor? Results of the Flosequinan‐ACE Inhibitor Trial (FACET) , 1993, Circulation.

[7]  R. Bain,et al.  Effects of vesnarinone on morbidity and mortality in patients with heart failure , 1993 .

[8]  M. Packer.  The search for the ideal positive inotropic agent. , 1993, The New England journal of medicine.

[9]  M. Brodsky,et al.  Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. , 1992, Circulation.

[10]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[11]  M. Vanantwerp,et al.  Epidemiology of End-Stage Heart Disease , 1991 .

[12]  R. Cody.  Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? I. Introduction. , 1988, Journal of the American College of Cardiology.

[13]  E. Braunwald,et al.  New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2. , 1986, The New England journal of medicine.

[14]  M. Packer,et al.  Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. , 1984, Circulation.